MIND CTI Reports First Quarter 2026 Results

MIND C.T.I. LTD. announced its financial results for the first quarter ended March 31, 2026, reporting revenues of $5.1 million and net income of $0.9 million, or $0.04 per share. While revenues remained similar to the previous year, net income saw an improvement. The company also provided updates on its share repurchase program and the Annual General Meeting, noting future challenges due to a major customer's non-renewal while exploring new opportunities in cloud, 5G, and AI.

Original reporting
Published May 11, 2026, 5:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 11, 2026, 5:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MIND CTI Reports First Quarter 2026 Results — source image
Decision brief

The 30-second read

$MNDONeutralLow
01

Why it matters

The non-renewal poses short-term risks, but growth initiatives in emerging tech sectors could provide long-term upside.

02

Market read

Limited immediate market impact; sector and regional effects are minimal, but company-specific developments are noteworthy for investors.

03

What to watch

Potential for new customer acquisitions or strategic partnerships that could mitigate revenue loss.

Relevance 6/10Timing: Moderate; quarterly earnings are relevant for short-term traders but already reflected in current prices.

Background

MIND C.T.I. LTD. is a technology firm with recent quarterly results indicating stable revenues and improved profitability, amidst challenges from a major customer non-renewal.

Company-level read

Ticker impact

$MNDONeutralMedium confidence
Context

Low relevance due to neutral sentiment and limited impact on broader markets.

Expected impact

Minimal short-term price movement expected; potential slight decline if major customer non-renewal impacts sentiment.

Evidence & confidence

Financial results are stable, but the loss of a major customer introduces uncertainty; growth prospects in emerging tech sectors could offset negatives.

Market effects

Potential negative impact on the technology sector due to customer non-renewal; however, growth in cloud, 5G, and AI sectors may offset this.

Limited regional impact; company operates primarily in its local markets.

Low; company size and market cap suggest minimal influence on global indices.

Counterpoint

The non-renewal may be an isolated incident; the company's diversification into cloud, 5G, and AI could lead to future growth.

Key entities

  • MIND C.T.I. LTD.

    A technology company focusing on communications and cloud solutions.

Related articles

$MNDOHigh

MIND CTI LTD (MNDO): Financial results for Q3 2026

MIND CTI LTD (MNDO) furnished an SEC Form 6-K — earnings release. Exhibit 1 MIND CTI to be Acquired by Enghouse Systems in All-Cash Transaction MIND CTI Reports Third Quarter 2026 Results Appointment of Orly Sorokin as New CEO Yoqneam, Israel, November 10, 2026 MIND C.T.I. LTD (NasdaqGM: MNDO ), a leading provider of convergent end-to-end prepa

$MNDOMed

MIND CTI LTD (MNDO): Financial results for Q2 2026

MIND CTI LTD (MNDO) furnished an SEC Form 6-K — earnings release. Exhibit 1 MIND CTI Reports Second Quarter 2026 Results * MIND Receives Nasdaq Notifications Yoqneam, Israel, August 6, 2026 MIND C.T.I. LTD. (NasdaqGM: MNDO ), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for servi

$JNJMed

Johnson & Johnson Reports Second Positive Phase 3 Study Of CAPLYTA In Bipolar Mania

Johnson & Johnson (JNJ) reported positive results from a second Phase 3 study of CAPLYTA for bipolar I disorder, meeting primary and secondary endpoints. The study showed a 3.7-point greater reduction in YMRS scores compared to placebo. JNJ plans to submit these findings to the FDA for approval. CAPLYTA is already approved for schizophrenia and depression. JNJ stock closed at $282.11, up 2.13%.

$ORCLMed

Bernstein Reiterates Outperform on Oracle’s AI Growth

Bernstein reiterated its Outperform rating and $325 price target for Oracle (NYSE: ORCL), citing an updated 10-year model that shows improved cash dynamics. The firm expects Oracle to reach positive free cash flow in about 18 months and not require additional external funding. Key catalysts include OpenAI's potential IPO and Oracle's free cash flow inflection.